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A number of epidemiological and experimental studies have implicated the non-selective herbicide,
paraquat, in the development of sporadic Parkinson's disease (PD). While preclinical research has focused
mainly on elucidating the nigrostriatal effects of paraquat, relatively little data are available concerning
non-motor brain systems and inﬂammatory immune processes (which have been implicated in PD).
Hence, in the present study, we sought to take a multi-system approach to characterize the inﬂuence of
paraquat upon extra-nigrostriatal brain regions, as well ascertain whether the impact of the pesticide
might be enhanced in the context of chronic intermittent stressor exposure. Our ﬁndings support the
contention that paraquat itself acted as a systemic stressor, with the pesticide increasing plasma corti-
costerone, as well as altering neurochemical activity in the locus coeruleus, paraventricular nucleus of
the hypothalamus, nucleus accumbens, dorsal striatum, and central amygdala. However, with the
important exception striatal dopamine turnover, the stressor treatment did not further augment these
effects. Additionally, paraquat altered inter-cytokine correlations and, to a lesser extent, circulating
cytokine levels, and concomitant stress exposure modulated some of these effects. Finally, paraquat
provoked signiﬁcant (albeit modest) reductions of sucrose preference and weight gain, hinting at
possible anhendonic-like or sickness responses. These data suggest that, in addition to being a well
known oxidative stress generator, paraquat can act as a systemic stressor affecting hormonal and
neurochemical activity, but largely not interacting with a concomitant stressor regimen.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Epidemiological data have for some time now supported a link
between Parkinson's disease (PD) and cumulative lifetime pesticide
exposure (Tanner et al., 2011; Wang et al., 2011; Kamel et al., 2013),id; 5-HT, serotonin; ANOVA,
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could be especially relevant for some of the neuropsychiatric
symptoms of the disease (Kim et al., 2013). Besides its effect on the
nigrostriatal system, exposure to paraquat in rodents has produced
other neurotoxic biological characteristics associated with PD
including microglia activation, Lewy-body like aggregates con-
taining a-synuclein, pro-inﬂammatory cytokine expression, and
oxidative stress via mitochondria complex inhibition or microglia
activation (Litteljohn et al., 2011a; Baltazar et al., 2014).
Upon entry into the brain, paraquat is distributed across areas
including the prefrontal cortex, hippocampus, olfactory bulbs, and
the substantia nigra pars compacta (SNc) (Peng et al., 2007). The
pesticide was also found to induce several PD-like non-motor
behavioural deﬁcits, including olfactory dysfunction (Czerniczyniec
et al., 2011), anxiety-like symptoms (Litteljohn et al., 2009;
Czerniczyniec et al., 2011; Campos et al., 2013), and memory
impairment (Chen et al., 2010). Nonetheless, it has yet to be
determined whether paraquat can induce anhedonic-like behav-
iour in rodents, and the need for understanding the pesticide'snder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In addition to biological insults, it is conceivable that psycho-
logically relevant stressors could affect the primary motor symp-
toms and neurodegenerative process (Urakami et al., 1988; Metz,
2007; Kibel and Drenjancevic-Peric, 2008; Smith et al., 2008), as
well as non-motor or co-morbid neuropsychiatric manifestations in
PD patients. For instance, major life events inﬂuenced the devel-
opment of depression among PD patients (Rod et al., 2013), and
psychological therapies have proven to be effective in reducing
depression and anxiety symptoms in PD patients (Yang et al., 2012;
Schrag et al., 2001; Hurt et al., 2012; Whitworth et al., 2013).
In the present investigation we sought to assess the individual
and combined effects of the PD-linked pesticide, paraquat, and a
psychologically relevant chronic intermittent immobilization/so-
cial defeat stressor (CIS) challenge. We were particularly interested
in further characterizing the inﬂuence of paraquat upon extra-
nigrostriatal brain regions and ascertaining whether the disparate
classes of stressors (chemical vs. psychological) would interact to
inﬂuence hedonic behaviour. It was also of interest to determine
whether any such effects would be accompanied by changes in
stressor hormone levels (corticosterone), central neurotransmitter
activity and immune messengers (circulating cytokines). Specif-
ically, it was hypothesized that chronic systemic paraquat admin-
istration and concurrent CIS exposure would provoke physiological
and behavioural changes consistent with a depressive-like pheno-
type, as expected in a sizable portion of PD patients.
2. Materials and methods
2.1. Animals and general experimental design
Male C57BL6/J mice were obtained at 6e7 weeks of age from
The Jackson Laboratory (Bar Harbor, ME, USA) and acclimated to
our vivarium for 2 weeks. Animals were singly housed in standard
polypropylene cages (27  21  14 cm) and maintained on a 12-h
light/dark cycle with lights on at 08:00 h. A diet of Ralston Purina
(St. Louis, MO)mouse chow andwater was provided ad libitum, and
room temperature was maintained at ~21 C. One week prior to the
commencement of the study, mice were randomly assigned to one
of four experimental conditions (No stress/Saline; No stress/Para-
quat; Stress/Saline; Stress/Paraquat) and sucrose preference
training initiated (n ¼ 10e12). A further 8 mice comprised the
testing-naïve negative control: except for behavioural testing (see
below), these animals received identical treatment to the No stress/
Saline mice. All animals were rapidly decapitated 2 h following the
ﬁnal paraquat or saline injection. In order to minimize the effects of
diurnal variations, tests and procedures were carried out between
the hours of 08:00 and 13:00. All experimental procedures were
approved by the Carleton University Committee for Animal Care
and complied with the guidelines set out by the Canadian Council
for the Use and Care of Animals in Research.
2.2. Experimental treatments: paraquat and chronic intermittent
stress
All mice received intraperitoneal injection with 10 mg/kg
paraquat (1,10-dimethyl-4,40-bipyridinium dichloride; Sigma
Aldrich, St Louis, MO, USA) or physiological saline (Sigma Aldrich).
Injections were administered twice a week for 6½ weeks (13 in-
jections in total) on a regular interval basis. This paraquat dose is
routinely used in our lab and has been shown to reliably induce
nigrostriatal damage (~25e35% neuron loss) (Mangano and Hayley,
2009; Mangano et al., 2011). During the 30 min immediately pre-
ceding each injection, half of the animals were either socially
defeated or physically restrained in semicircular Plexiglas tubes(4  12 cm) with tails taped to prevent turning. The social defeat
paradigm involved introducing experimental mice into the home-
cage of a signiﬁcantly larger and more aggressive mouse (retired
CD1 breeders from Charles River, QC, CAN). A mesh wire divider
was inserted into the cage upon the ﬁrst display of submissive
behaviour (upright posture with belly exposed) or if excessive
ﬁghting occurred (continuous biting); this had the effect of physi-
cally separating the mice while still allowing for interactions be-
tween them (Audet et al., 2011). Stressor application followed a
ﬁxed alternating schedule such that each mouse in the stressor
groups received one session per week of restraint and one of social
defeat. On the day of sacriﬁce all animals in the stressor conditions
received 30 min restraint immediately prior to the ﬁnal paraquat or
saline injection. Due to the nature of the stressor paradigm, the
stressed animals were housed in holding rooms separate from, but
otherwise identical to, their non-stressed counterparts.2.3. Brain dissection technique
Following rapid decapitation, brains were excised and sectioned
into sequential coronal slices using razor blades and a chilled
stainless steel microdissecting matrix with adjacent slots spaced
~0.5 mm apart. Hollow biopsy needles were used to collect the
dorsal striatum, paraventricular nucleus of the hypothalamus
(PVN), locus coruleus (LC) and nucleus accumbens. All tissue
samples were taken with reference to the mouse brain atlas of
Franklin and Paxinos (1997). Samples were maintained in a ho-
mogenizing solution containing 14.17 g monochloroacetic acid,
0.0186 g disodium ethylenediamine tetraacetate (EDTA), 5.0 ml
methanol, and 500 ml H2O; and stored at 80 C until determi-
nation of central monoamine and metabolite levels using high
performance liquid chromatography (HPLC).2.4. Plasma corticosterone assay
At the time of decapitation, trunk blood from all of the animals,
including those in the behavioural testing-naive control group, was
collected in tubes containing 10 mg EDTA. Samples were centrifuged
(3000g for 8 min) and the plasma removed and stored in aliquots
at80 C for later corticosterone determinationwith commercially
available radioimmunoassay kits (ICN Biomedicals, CA, USA).
Samples were assayed in duplicate within a single run to control for
inter-assay variability; the intra-assay variability was less than 10%.
Separate plasma aliquots were used for the cytokine
determinations.2.5. Plasma cytokine quantiﬁcation
Circulating levels of 11 different cytokines were determined by
multiplex analysis using the Luminex 100 suspension-based bead
array system (Luminex Corp., Austin, TX) and a custom multiple
cytokine detection kit (MILLIPLEX MAP Mouse Cytokine/Chemo-
kine Kit, Millipore, Cat. #MPXMCYTO-70K). Each of the 11 cyto-
kines assayed are listed in Table 1. The assay was performed
according to the kit manufacturer's instructions (see www.
millipore.com/userguides) and, unless otherwise indicated, all re-
agents were provided in the multiplex kit. Eight samples from each
of the four treatment groups were run in duplicate; the remaining
samples were singly run. Where applicable, results of duplicate
sample determinations were averaged prior to the data being
analysed. In cases where cytokine levels were so low as to be un-
detectable, samples were assigned a value of one-half the lower
limit of quantitation.
Table 1
List of assayed plasma cytokines, brain monoamines and amine metabolites.
Analyte name/symbol Full name
Cytokine
IFN-g Interferon-gamma
GM-CSF Granulocyte-macrophage colony-stimulating factor
IL-1b Interleukin-1-beta
IL-6 Interleukin-6
IL-10 Interleukin-10
IL-12 (p40) Interleukin-12 (p40)
IL-12 (p70) Interleukin-12 (p70)
IL-17 Interleukin-17
MCP-1 Monocyte chemoattractant protein-1
MIP-1a Macrophage inﬂammatory protein-1-alpha
TNF-a Tumour necrosis factor-alpha
Monoamine/metabolite
DA Dopamine
DOPAC 3,4-Dihydroxyphenylacetic acid
HVA Homovanillic acid
NE Norepinephrine
MHPG 3 Methoxy-4-hydroxyphenylglycol
5-HT Serotonin
5-HIAA 5-Hydroxyindole acetic acid
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concentrations
Regional brain levels of monoamines and their primary me-
tabolites (see Table 1) were determined by HPLC in keeping with
previously reported methods (Litteljohn et al., 2014). Tissue
punches were homogenized by ultrasonic disruption (Sonic Dis-
membrator Model 100, Fisher Scientiﬁc) in the homogenizing so-
lution inwhich theywere initially frozen (with DHBA as an internal
standard). The level of protein was determined with the Pierce BCA
Protein Assay Kit (Thermo Scientiﬁc 23225). Homogenized samples
were centrifuged (12,000 rpm for 3min at 4 C), after which 50 ml of
supernatant was injected, at a ﬂow rate of 1 ml/min, into the
automated HPLC system (Agilent 1100) with electrochemical de-
tector (DECADE II SDC, Antec) and ZORBAX Eclipse XDB-C8 col-
umns (Agilent: 4.6 mm inner diameter, 150 mm length, 5 mm
particle size; thermostated at 40 C); the oxidation potential was
maintained at 0.60 V. The mobile phase comprised: 90 mM sodium
phosphate monobasic, 1.7 mM 1-octanesulfonic acid, 50 mM EDTA,
10% acetonitrile, 50 mM citric acid (monohydrate), 5 mM KCL, and
HPLC-grade water. Monoamine and metabolite concentrations
were expressed relative to the protein content of the samples, and
ﬁnal results presented as ng/mg protein (Litteljohn et al., 2014).2.7. Repeated sucrose preference testing
Baseline sucrose preference training was undertaken during the
seven days leading up to the start of the experiment. Brieﬂy, singly
housed mice were presented with two identical 15 ml ball-bearing
sipper tubes (introduced into the home-cage through spaces in the
cage lid), one of which contained regular tap water and the other a
1% palatable sucrose solution. Animals were permitted ad-lib ac-
cess to both of the bottles, which were weighed at the same time
each morning and the amount consumed from each recorded.
Bottles were rotated daily and across weeks to offset potential
positional preferences. Sucrose preference was calculated accord-
ing to the formula: Sucrose preference ¼ [sucrose intake/(sucrose
intake þ water intake)]  100. In this way, 24-h baseline sucrose
preference levels were established for the animals prior to initi-
ating any of the experimental treatments. Only those mice
demonstrating a steady baseline sucrose preference (average su-
crose preference over the ﬁnal 2 baseline training days >75%) wereused in the study; all but 1 mouse met or surpassed the pre-
determined cut-off value. Each week commencing at 60 min after
the second of the two weekly injections/stressors, animals were
permitted free access for 3 consecutive days to the water and su-
crose solutions. To avoid capturing any acute toxic effects of the
pesticide, recovery day data (corresponding to the 24-h period
commencing the morning after the most recent treatment appli-
cation) were collected and analysed.
Although we considered the repeated sucrose-testing paradigm
to be non-invasive and minimally stressful, an additional cohort of
animals was included to explicitly assess the degree of stress
associated with the testing regimen. To this end, blood samples
from the testing-naïve control micewere assayed for corticosterone
concentration, and the data included in the between-groups anal-
ysis. It was decided a priori that a statistically signiﬁcant difference
in plasma corticosterone levels between the two non-stressed, sa-
line-treated control groups (assessed via the two-sample t-test,
p < 0.05) would be considered evidence of a testing-related
stressor-like effect and, as such, would warrant inclusion of
testing-naïve samples in (or at the minimum alter the interpreta-
tion of the results from) the subsequent cytokine and monoamine
assessments. In fact, this was not the case following this analysis.
2.8. Statistical analyses
Data were analysed by 2 (Injection; saline v. paraquat) 2
(Stress; no stress v. stress) ANOVAs followed by Fisher's planned
comparisons (p < 0.05) where appropriate. Where applicable,
repeated measures ANOVAs were conducted with Time as the 3rd
independent variable. In instances where it was of interest to assess
the linear relationship between outcome variables (e.g., cytokine
network analysis), this was done via Pearson product moment
correlations (r) and, in certain cases, coefﬁcients of determination
(r2). As numerous correlations were conducted, the a level of sta-
tistical signiﬁcance was set to <0.025, per the method of Poulter
et al. (2010). In addition, we ran c2 analyses to determine
whether the frequency of signiﬁcant cytokine correlations differed
between the treatment groups (p < 0.05). During the course of
tissue dissection and HPLC analyses a few samples were lost. For
the sucrose preference test, data points exceeding 2 standard de-
viationswere deemed outlier values and omitted from the analyses.
Data were evaluated using a StatView (version 6.0) statistical
software package and visualized with GraphPad Prism 6 (La Jolla,
CA). The latter program was also used for the c2 analyses.
3. Results
3.1. Plasma cytokine levels and inter-correlations were altered by
paraquat and stress
As shown in Fig. 1A, paraquat increased the circulating con-
centrations of the haematopoietic colony-stimulating factor, GM-
CSF (F1, 35 ¼ 4.75, p < 0.05). None of the other assayed cytokine
species were signiﬁcantly affected by the pesticide treatment (with
respect to absolute protein levels; data not shown). As it relates to
the CIS treatment, IL-6 levels were signiﬁcantly elevated overall
following stressor exposure (F1, 34 ¼ 5.62, p < 0.05), though the
magnitude of this effect was quite small and the absolute levels of
this cytokine rather low across all groups (Fig. 1A). In contrast,
plasma levels of the IL-12 subunit, IL-12 (p40), were reduced in
mice receiving the stressor treatment, irrespective of pesticide
exposure (F1, 32 ¼ 4.24, p < 0.05).
Fig. 1B shows the cross-correlations between the different cy-
tokines among non-stressed (top panel) and stressed mice (bottom
panel) as a function of saline (left matrices) and paraquat treatment
Fig. 1. Concentrations of select cytokines following treatment with paraquat and/or a chronic intermittent stressor (Panel A). Whereas the pesticide increased the circulating levels
of granulocyte macrophage colony stimulating factor (GM-CSF), the stressor increased interleukin-6 (IL-6) and decreased IL-12 (p40) concentrations; no interaction effects were
observed. Panel B shows the cross-correlations between the different cytokines among non-stressed (top panel) and stressed mice (bottom panel) as a function of saline (left
matrices) and paraquat treatment (right matrices). Precise correlation values are presented within the individual squares of each matrix and the squares are colour-coded so as to
better reﬂect the patterns of correlations: Green and blue indicate signiﬁcant positive and negative correlations, respectively (p < 0.025), while grey denotes a lack of statistical
signiﬁcance (see text for additional details). *p < 0.05 relative to saline-treated mice (collapsed across the stressor treatment); yp < 0.05 relative to non-stressed mice (collapsed
across the paraquat treatment).
C. Rudyk et al. / Neurobiology of Stress 2 (2015) 85e9388(right matrices). Precise correlation values are presented within the
individual squares of each matrix and the squares are colour-coded
so as to better reﬂect the patterns of correlations: green and blue
indicate signiﬁcant positive and negative correlations, respectively
(p < 0.025), while grey denotes a lack of statistical signiﬁcance.
Among the saline-treated animals, very few correlations were
found to be statistically signiﬁcant and their frequency (3 positive
correlations in the non-stressed group, 1 positive and 1 negative
correlation in the stressed condition) was unaffected by the
stressor treatment (c2 ¼ 0.21, df ¼ 1, p ¼ 0.65). Yet, it should be
noted that the stressor did abolish the few signiﬁcant correlations
that were observed among the non-stressed saline controls, and
seemed to selectively inﬂuence correlations involving GM-CSF
(Fig. 1B).Following paraquat treatment, the frequency of signiﬁcant
cytokine correlations among the non-stressed mice increased from
3 (of a possible 66 correlations) to 17 (c2 ¼ 9.96, df ¼ 1, p < 0.01),
and all of these associations were positive and ranged in strength
fromweak (0.4 < r2 < 0.5) to very strong (r2 > 0.9). As can be seen in
Fig. 1B, almost half (8 out of 17) of the signiﬁcant correlations in the
No stress/Paraquat condition involved IL-10 and GM-CSF, and these
cytokines themselves demonstrated a moderate linear relationship
(r2 ¼ 0.59). Perhaps even more striking was the marked difference
in the proﬁle of signiﬁcant paraquat-associated cytokine correla-
tions among the non-stressed vs. stressed mice. Whereas in the
former group, paraquat clearly enhanced the rigidity of the pe-
ripheral cytokine network, no such effect was apparent in the latter
group (relative to the stressor alone-treated mice) (Fig. 1B). In fact,
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associated cytokine correlations from 17 to 2 (c2 ¼ 12.05, df ¼ 1,
p < 0.001).
3.2. Paraquat increased plasma corticosterone concentrations as
well as monoamine activity in the LC and PVN
There was no difference in plasma corticosterone content be-
tween the non-stressed, saline-treated control mice that under-
went behavioural testing and the testing-naïve negative controls
(t14 ¼ 0.68, p > 0.50: 6.57 ± 0.66 v 5.76 ± 1.06). Accordingly, pooled
data from these two groups were used for the between-groups
corticosterone analysis (n ¼ 16). The 2-way ANOVA indicated that
plasma corticosterone concentrations were modestly but signiﬁ-
cantly increased following treatment with either paraquat or the
stressor (Fs1, 43 ¼ 4.26 and 4.52, respectively, p < 0.05). As depicted
in Fig. 2A, while the interaction effect of Paraquat with Stress was
not statistically signiﬁcant (p > 0.10), levels of the stress hormone
appeared to be highest among mice receiving the combination
treatment.
In addition to augmenting plasma corticosterone, paraquat
increased NE concentrations within the locus coeruleus (LC) (F1,
33¼ 6.62, p < 0.05) and PVN (F1, 27¼ 33.31, p < 0.0001) among non-
stressed and stressed mice alike (Fig. 2B). In contrast, within these
brain regions, paraquat did not signiﬁcantly alter the levels of the
primary NE metabolite, MHPG. While the PVN concentrations of 5-
HT, 5-HIAA and DA were likewise unchanged following the pesti-
cide treatment, accumulation of the DA metabolites, DOPAC and
HVA, was signiﬁcantly enhanced overall among the paraquat-
treated animals (Fs1, 27 ¼ 7.37 and 13.3, p < 0.05: 7.63 ± 1.17 v
13.56 ± 2.42 and 10.74 ± 1.15 v 15.38 ± 1.27, respectively).
The chronic intermittent stressor had comparatively less inﬂu-
ence than paraquat on LC and PVN monoaminergic activity. Still,
within the PVN, levels of both 5-HT (F1, 27 ¼ 9.34, p < 0.01; see
Fig. 2A) and HVA (F1, 27¼ 10.18, p < 0.01: 11.14 ± 1.20 v 15.29 ± 1.22)
were signiﬁcantly elevated overall among animals undergoing the
stressor treatment.Fig. 2. Inﬂuence of paraquat and chronic intermittent stress on elements of the murine stres
corticosterone levels (A). As shown in panel B, paraquat augmented norepinephrine (NE) co
latter region, stress also increased serotonin (5-HT) levels. *p < 0.05 relative to saline-treat3.3. Altered dopaminergic activity within the nucleus accumbens
and dorsal striatum following paraquat and stressor exposure
Within the reward-relevant nucleus accumbens, DA levels var-
ied as a function of the signiﬁcant interaction between Pesticide
and Stress (F1, 38¼ 6.53, p < 0.05). As shown in Fig. 3 and conﬁrmed
by the follow-up comparisons, while accumbal DA concentrations
were diminished (to a similar level) by treatment with either
paraquat or CIS (p < 0.05), combining the two insults did not lead to
a further decrement in parent amine levels. Separate ANOVAs also
revealed signiﬁcant Pesticide  Stress interaction effects for DOPAC
and HVA levels (Fs1, 38 ¼ 10.17 and 8.77, respectively, p < 0.01).
Whereas in the former case, pesticide exposure normalized the
stressor-induced elevation of DOPAC, in the latter case paraquat
interacted with the stressor treatment to enhance accumbal HVA
accumulation (p < 0.01 compared to all other groups) (Fig. 3). The
overall effect(s) of the experimental treatments on DA utilization in
the nucleus accumbens can perhaps best be appreciated by exam-
ining the rate of DA turnover (i.e., the ratio of DA metabolites to
DA); not surprisingly, this was also noted to vary as a function of a
signiﬁcant Paraquat Stress interaction (F1, 38¼ 7.72, p < 0.01). The
post-hoc analyses conﬁrmed that the pesticide and stressor each
provoked a signiﬁcant increase in the DA metabolite-to-parent
amine ratio (p < 0.01 relative to the non-stressed, saline-treated
controls).
Within the dorsal striatum, there were no signiﬁcant effects of
paraquat or the CIS treatment on DA concentrations (Fig. 4). How-
ever, higher HVA levels were observed among mice receiving the
pesticide treatment (F1, 37 ¼ 7.04, p < 0.05), and a signiﬁcant
Pesticide  Stress interaction was revealed for striatal DOPAC (F1,
37 ¼ 7.30, p < 0.05). Speciﬁcally, mice that received either the
paraquat alone or stressor alone treatments displayed diminished
DOPAC concentrations relative to the non-stressed, saline-treated
animals (p < 0.05). Contrastingly, DOPAC levels in the paraquat-
plus-stressor-treated mice were unchanged compared to controls
(Fig. 4). The pattern of paraquat-and-stressor-associated dopami-
nergic changes suggested that the combination treatment had thes response. Both paraquat and stress signiﬁcantly (but independently) increased plasma
ncentrations within the locus coeruleus (LC) and paraventricular nucleus (PVN); in the
ed animals; yp < 0.05 relative to non-stressed mice.
Fig. 3. Dopaminergic activity in the nucleus accumbens as a function of paraquat and stressor exposure. The non-stressed, saline-treated controls had higher dopamine (DA) levels
(top left) and diminished DA turnover rates (bottom right) compared to all other treatment groups. Also depicted are the data for 3,4-Dihydroxyphenylacetic acid (DOPAC; bottom
left) and homovanillic acid (HVA; top right) (see text for more details). *p < 0.05 relative to saline-treated, non-stressed controls; yp < 0.05 relative to saline-plus-stressor-treated
mice.
Fig. 4. Dopaminergic activity in the dorsal striatum as a function of paraquat and stressor exposure. Co-treatment with paraquat and stress had the effect of increasing dopamine
(DA) turnover within the dorsal striatum (in the absence of altered parent amine levels). Also depicted are the data for striatal 3,4-Dihydroxyphenylacetic acid (DOPAC; bottom left)
and homovanillic acid (HVA; top right) levels (see text for more details). *p < 0.05 relative to saline-treated mice (collapsed across stressor exposure); yp < 0.05 relative to saline-
plus-stressor-treated mice.
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to what was previously seen in immobilization-plus-MPTP-treated
mice (Urakami et al., 1988). This was borne out by the ANOVA,
which revealed a signiﬁcant Pesticide  Stress interaction effect on
DA turnover (F1, 37 ¼ 5.70, p < 0.05). As shown in Fig. 4 and
conﬁrmed by the post-hoc tests, only those animals co-treatedwith
paraquat and stress displayed enhanced DA turnover in the stria-
tum (p < 0.05).
3.4. Stressor and paraquat effects on sucrose consumption and
weight gain
Although there was no signiﬁcant main effect for the stressor
treatment nor were there any signiﬁcant interactions between anyof the variables, the repeated measures ANOVA indicated that
paraquat itself had the overall effect of reducing animals' prefer-
ence for a palatable sucrose-containing solution (F1, 33 ¼ 5.55,
p < 0.05). Despite the lack of signiﬁcant interaction effects of
Paraquat with Stress or Time, from Fig. 5 (top) it is clear that the
paraquat effect developed gradually over time and that the pesti-
cide had its most pronounced effect in mice that were also exposed
to the stressor. Indeed, the multiple comparisons indicated that the
paraquat-plus-stressor-treated animals were the only ones to
exhibit signiﬁcant decrements in sucrose preference and this
occurred at Weeks 4, 5 and 6 (p < 0.05 relative to saline-treated
controls). Assessment of difference between baseline and Weeks
6, indicated that the stress alone group was identical to controls
and the paraquat alone treatment caused only a 1.5% sucrose
Fig. 5. The top and bottom line graphs depict sucrose preference and weight,
respectively, across time as a function of paraquat treatment and chronic intermittent
stress. As shown in the top panel, paraquat treated animals had decreased sucrose
preference beginning at Week 4; this effect was clearly most prominent in animals
receiving concomitant stressor exposure (see text for additional details). The bottom
graph shows the diminished weight evident at Weeks 4e6 in paraquat or stressor
treated mice, relative to the non-stressed saline treated mice. *p < 0.05 relative to
saline-treated animals.
C. Rudyk et al. / Neurobiology of Stress 2 (2015) 85e93 91reduction, however, the paraquat þ stress treatment promoted a
modest but statistically signiﬁcant 9% reduction in sucrose prefer-
ence at Week 6 relative to baseline.
As shown in Fig. 5 (bottom), mice receiving either paraquat or
the stressor gained slightly but signiﬁcantly less weight overall
than saline-treated controls. Speciﬁcally, there were signiﬁcant
Paraquat Time and Stress  Time interactions (Fs5, 230 ¼ 4.58 and
11.83 respectively, p < 0.01). Parallelling the time-dependent su-
crose effects, the comparisons revealed diminished weight at
Weeks 4e6 in paraquat or stressor treated mice (p < 0.05). How-
ever, in contrast to the sucrose variations, no further weight loss
was noted among animals in the paraquat-plus-stressor condition,
relative to either of the treatments administered alone. Addition-
ally, neither of the treatments was observed to provoke any overt
sickness behaviour (piloerection, lethargy, ptosis).4. Discussion
Not only does co-morbid depressive illness pose a major threat
to quality of life among PD patients, there is evidence to suggest
that depression can actually inﬂuence the severity and clinical
management of PD motor symptoms e and perhaps even affect the
progression of the underlying neurodegenerative process (Backer,
2000; Smith et al., 2002; Metz et al., 2005; Kibel and
Drenjancevic-Peric, 2008; Pålhagen et al., 2008; Smith et al.,2008; Hemmerle et al., 2012; van Dijk et al., 2013). The current
ﬁndings are consistent with a growing number of reports sug-
gesting that environmental toxicants, and pesticides in particular,
may play a role in the development of not only motor impairment,
but also non-motor symptoms that are often evident in PD
(McDowell and Chesselet, 2012; Freire and Koifman, 2012). Indeed,
in the case of paraquat alone, a number of groups have found evi-
dence of both cognitive and anxiety-like symptoms in infrahuman
chronic exposure models, and it appears likely that oxidative, in-
ﬂammatory and potentially even neuroplastic changes occurring in
the hippocampus and, to a lesser extent the prefrontal cortex, are
implicated in this regard (Litteljohn et al., 2009; Chen et al., 2010;
Czerniczyniec et al., 2011; Mangano et al., 2011; Mitra et al., 2011;
Songin et al., 2011; Desplats et al., 2012).
Although scant data are available regarding the potential
emotional or affective behavioural effects of paraquat, a very recent
study found that, in rats, chronic low-dose exposure to paraquat
(delivered via osmotic minipumps) induced behavioural signs of
learned helplessness in a forced swim test (Campos et al., 2013).
Yet, it should be underscored that the Campos et al. (2013) study
did not uncover any signs of anhedonia (or cognitive dysfunction
for that matter) among the paraquat-treated rats. Seeing as how in
the present study the paraquat-induced sucrose preference deﬁcits
were only observed in the CIS co-treated animals, it may be the case
that exposure to paraquat alone is insufﬁcient to cause such deﬁ-
cits, and that another overlapping insult, such as intermittent
exposure to psychologically-relevant stress, is needed to fully
“unmask” any underlying neurobehavioural deﬁcit.
The fact that animals receiving the paraquat or stressor treat-
ments gained signiﬁcantly less weight over time compared to
control mice raises the possibility that the sucrose deﬁcits might be
related to generalized toxicity or non-speciﬁc stressor effects. Yet, it
is important to note that, unlike the weight loss, the sucrose
reduction was only evident in mice that received the combination
of stressor þ paraquat treatments. It also warrants reiterating that
the sucrose preference test data were collected between 24 and
48 h after pesticide and/or stressor application (i.e., on the “re-
covery day”), thus limiting any potential confounds related to the
possible acute “toxic” effects of either of the treatments. Of course,
it should be noted that the observed effects were modest and the
fact that the stressor alone had little effect on sucrose is an
important caveat in this study. Indeed, we are not able to say that
the stressor and paraquat treatment really had any synergistic or
additive effects, but rather simply that the combination was
required to observe any signiﬁcant effect at all.
Of course, the obvious question then becomes: “What are the
biological mechanisms responsible for this behavioural phenome-
non?” In the present investigation we examined four distinct but
not mutually exclusive possibilities, namely treatment-induced
alterations of: 1) HPA activity (i.e., the classical “stress response”),
2) concentrations and network activity of circulating cytokines (i.e.,
the peripheral “immunological response”), 3) dopaminergic
neurotransmission at the nucleus accumbens (i.e., mesolimbic
reward circuitry), and 4) striatal DA activity (i.e., nigrostriatal motor
pathway).
. It will be recalled that only in the paraquat-plus-stressor group
was striatal DA utilization signiﬁcantly increased. It is thus
tempting to speculate that the combination-treated mice were, in
fact, hit “harder” than the paraquat alone-treated animals, and a
prospective “compensatory response” (Kuter et al., 2007; Biju and
de la Fuente-Fernandez, 2009) proved sufﬁcient to stave off stria-
tal DA depletion. While much evidence points to the critical
involvement of nucleus accumbens DA dysfunction in the devel-
opment of anhedonic-like symptoms (Remy et al., 2005), there's
certainly precedent for suggesting that alterations of striatal
C. Rudyk et al. / Neurobiology of Stress 2 (2015) 85e9392(caudate/putamen) DA signalling could also play a role. For instance
Tadaiesky et al. (2008), reported that striatal and PFC alterations of
DA, as well as 5-HT and NE, are the likely cause of emotional and
cognitive disturbances induced by 6-OHDA administration in rats.
These ﬁndings were largely recapitulated in a 2010 study by San-
tiago and colleagues, which also implicated deﬁcits in hippocampal
5-HT signalling. While not explicitly addressed in the present
investigation, ﬁndings from our laboratory have indicated that
paraquat also inﬂuence monoamine activity (5-HT, NE and DA) in
the hippocampus and prefrontal cortex (reviewed in Litteljohn
et al., 2011b).
Recent work has established a connection between circulating
pro-inﬂammatory cytokines and depressive-like symptoms in PD
patients (Menza et al., 2010; Lindqvist et al., 2012). In the present
study, however, neither paraquat nor the CIS treatment provoked
many signiﬁcant changes in absolute cytokine concentrations. Yet,
the pesticide did increase circulating levels of the haematopoietic
colony-stimulating factor, GM-CSF. Since we and others have
already demonstrated the capacity of this trophic cytokine to pro-
tect against the neurodegeneration caused by paraquat and other
environmental insults (Nakagawa et al., 2006; Huang et al., 2007;
Choudhury et al., 2011; Mangano et al., 2011), it seems reasonable
to suggest that the presently observed GM-CSF increase represents
a compensatory homoeostatic response to xenobiotic challenge.
Despite the paucity of cytokine changes, we did ﬁnd that para-
quat imposed a distinct “rigidity” on the circulating cytokine
network that was abolished by co-administration of the stressor
regimen. Particularly intriguing were the positive correlations be-
tween pro-inﬂammatory cytokines (IFN-g, TNF-a, IL-17, MIP-1a)
and the pro-trophic cytokine, GM-CSF, and the anti-inﬂammatory
cytokine, IL-10. In effect, our data hint at a heightened coordina-
tion of peripheral cytokine network action among mice exposed
only to paraquat, and a capacity of psychological stress to disrupt
such network responding. The task of assigning an overall ‘valence’
to the observed cytokine changes is not straightforward (Litteljohn
and Hayley, 2012). Nonetheless, it is our contention that increasing
the rigidity of the cytokine network likely constitutes an adaptive
response to xenobiotic insult, serving to better position the or-
ganism to combat further challenges.
Our ﬁndings indicate that paraquat affects HPA activity, pe-
ripheral cytokines, and mesolimbic and nigrostriatal DA turnover,
some of which might be relevant for the development of
depressive-like behaviours. Moreover, it appears that psychological
stressors are capable of modulating some of the brain and behav-
iour effects of paraquat. These data could have implications for how
chronic stress is perceived and managed in a neurological context
or among individuals with a known history of environmental
toxicant exposure.
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